Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial

Ting Fan LeungDepartment of Paediatrics; The Chinese University of Hong Kong; Shatin, Hong KongCorrespondence[email protected]

Anthony Pak-Yin LiuDepartment of Paediatrics and Adolescent Medicine; Li Ka Shing Faculty of Medicine; The University of Hong Kong; Hong Kong

Fong Seng LimNational Healthcare Group Polyclinics and National University of Singapore; Singapore

Franck ThollotAssociation Française de Pédiatrie Ambulatoire (AFPA); Essey Les Nancy, France

Helen May Lin OhDivision of Infectious Disease; Changi General Hospital; Singapore

Bee Wah LeeMount Elizabeth Medical Center and National University of Singapore; Singapore

Lars RomboCentre for Clinical Research; Sormland County Council; Uppsala University and Karolinska Institute; Stockholm, Sweden

Ngiap Chuan TanSingHealth Polyclinics and DUKE-NUS Graduate Medical School; Singapore

Roman RouzierInstitut Curie; Paris, France

Damien FrielGSK Vaccines; Wavre, Belgium

Benoit De MuynckGSK Vaccines; Wavre, Belgium

Stéphanie De SimoniGSK Vaccines; Rixensart, Belgium

Pemmaraju SuryakiranGlaxoSmithKline Pharmaceuticals India Ltd.; Bangalore, India

Marjan HezarehChiltern International for GSK Vaccines; Wavre, Belgium

Nicolas FolschweillerGSK Vaccines; Wavre, Belgium

Florence ThomasGSK Vaccines; Wavre, Belgium

Frank StruyfGSK Vaccines; Wavre, Belgium

Your download is now in progress and you may close this window